$46.30
0.390.85%
At Close: -
$46.30
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Legend Biotech
LEGNNASDAQ
want to know what
the Bulls & Bears Say?
Legend Biotech (NASDAQ:LEGN) Stock, Analyst Ratings, Price Targets, Forecasts
Legend Biotech Corp has a consensus price target of $60.32 based on the ratings of 69 analysis. The 3 most-recent analyst ratings were released by BMO Capital, HC Wainwright & Co., and RBC Capital on July 3, 2024, July 3, 2024, and June 21, 2024, respectively. With an average price target of $83 between BMO Capital, HC Wainwright & Co., and RBC Capital, there's an implied 79.27% upside for Legend Biotech Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
BMO Capital
HC Wainwright & Co.
RBC Capital
Piper Sandler
Truist Securities
1calculated from analyst ratings
Analyst Ratings for Legend Biotech
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/03/2024 | Buy Now | 94.38% | BMO Capital | Kostas Biliouris | $90 → $90 | Maintains | Outperform | Get Alert |
| 07/03/2024 | Buy Now | 57.67% | HC Wainwright & Co. | Mitchell Kapoor | $73 → $73 | Reiterates | Buy → Buy | Get Alert |
| 06/21/2024 | Buy Now | 85.75% | RBC Capital | Leonid Timashev | $86 → $86 | Reiterates | Outperform → Outperform | Get Alert |
| 06/17/2024 | Buy Now | 94.38% | Piper Sandler | Edward Tenthoff | $90 → $90 | Reiterates | Overweight → Overweight | Get Alert |
| 06/17/2024 | Buy Now | 90.06% | Truist Securities | Asthika Goonewardene | → $88 | Initiates | → Buy | Get Alert |
| 06/06/2024 | Buy Now | 57.67% | HC Wainwright & Co. | Mitchell Kapoor | $73 → $73 | Reiterates | Buy → Buy | Get Alert |
| 06/04/2024 | Buy Now | 57.67% | HC Wainwright & Co. | Mitchell Kapoor | $73 → $73 | Reiterates | Buy → Buy | Get Alert |
| 05/24/2024 | Buy Now | 57.67% | HC Wainwright & Co. | Mitchell Kapoor | $86 → $73 | Maintains | Buy | Get Alert |
| 05/23/2024 | Buy Now | 29.59% | Deutsche Bank | James Shin | → $60 | Initiates | → Buy | Get Alert |
| 05/14/2024 | Buy Now | 85.75% | RBC Capital | Leonid Timashev | $85 → $86 | Maintains | Outperform | Get Alert |
| 05/14/2024 | Buy Now | 85.75% | HC Wainwright & Co. | Mitchell Kapoor | $87 → $86 | Maintains | Buy | Get Alert |
| 05/09/2024 | Buy Now | 87.9% | HC Wainwright & Co. | Mitchell Kapoor | → $87 | Reiterates | Buy → Buy | Get Alert |
| 04/23/2024 | Buy Now | 87.9% | HC Wainwright & Co. | Mitchell Kapoor | → $87 | Reiterates | Buy → Buy | Get Alert |
| 04/17/2024 | Buy Now | 40.39% | Scotiabank | George Farmer | $65 → $65 | Upgrade | Sector Perform → Sector Outperform | Get Alert |
| 04/16/2024 | Buy Now | 87.9% | HC Wainwright & Co. | Mitchell Kapoor | → $87 | Reiterates | Buy → Buy | Get Alert |
| 04/03/2024 | Buy Now | 77.11% | Cantor Fitzgerald | Rick Bienkowski | → $82 | Initiates | → Overweight | Get Alert |
| 04/01/2024 | Buy Now | 87.9% | HC Wainwright & Co. | Mitchell Kapoor | → $87 | Reiterates | Buy → Buy | Get Alert |
| 03/18/2024 | Buy Now | 74.95% | UBS | Ashwani Verma | $76 → $81 | Maintains | Buy | Get Alert |
| 03/18/2024 | Buy Now | 87.9% | HC Wainwright & Co. | Mitchell Kapoor | → $87 | Reiterates | Buy → Buy | Get Alert |
| 03/13/2024 | Buy Now | 87.9% | HC Wainwright & Co. | Mitchell Kapoor | → $87 | Reiterates | Buy → Buy | Get Alert |
| 03/13/2024 | Buy Now | 85.75% | Raymond James | Sean McCutcheon | → $86 | Initiates | → Outperform | Get Alert |
| 03/12/2024 | Buy Now | 83.59% | RBC Capital | Leonid Timashev | → $85 | Reiterates | Outperform → Outperform | Get Alert |
| 03/08/2024 | Buy Now | 83.59% | RBC Capital | Leonid Timashev | → $85 | Reiterates | Outperform → Outperform | Get Alert |
| 03/07/2024 | Buy Now | 83.59% | RBC Capital | Leonid Timashev | → $85 | Reiterates | Outperform → Outperform | Get Alert |
| 01/24/2024 | Buy Now | 103.02% | Barclays | Gena Wang | $93 → $94 | Maintains | Overweight | Get Alert |
| 12/22/2023 | Buy Now | 87.9% | HC Wainwright & Co. | Mitchell Kapoor | → $87 | Reiterates | Buy → Buy | Get Alert |
| 12/19/2023 | Buy Now | 40.39% | Scotiabank | George Farmer | → $65 | Initiates | → Sector Perform | Get Alert |
| 11/15/2023 | Buy Now | 87.9% | HC Wainwright & Co. | Mitchell Kapoor | $86 → $87 | Maintains | Buy | Get Alert |
| 10/18/2023 | Buy Now | 100.86% | Barclays | Gena Wang | $92 → $93 | Maintains | Overweight | Get Alert |
| 10/18/2023 | Buy Now | 85.75% | HC Wainwright & Co. | Mitchell Kapoor | $85 → $86 | Maintains | Buy | Get Alert |
| 08/16/2023 | Buy Now | 83.59% | HC Wainwright & Co. | Mitchell Kapoor | → $85 | Reiterates | Buy → Buy | Get Alert |
| 07/21/2023 | Buy Now | 83.59% | HC Wainwright & Co. | Mitchell Kapoor | $82 → $85 | Maintains | Buy | Get Alert |
| 07/21/2023 | Buy Now | 98.7% | Barclays | Gena Wang | $90 → $92 | Maintains | Overweight | Get Alert |
| 07/20/2023 | Buy Now | 83.59% | Morgan Stanley | Matthew Harrison | $65 → $85 | Maintains | Overweight | Get Alert |
| 06/16/2023 | Buy Now | 79.27% | RBC Capital | Leonid Timashev | → $83 | Reiterates | Outperform → Outperform | Get Alert |
| 06/13/2023 | Buy Now | 94.38% | BTIG | Justin Zelin | $85 → $90 | Maintains | Buy | Get Alert |
| 06/08/2023 | Buy Now | 77.11% | HC Wainwright & Co. | Mitchell Kapoor | → $82 | Reiterates | Buy → Buy | Get Alert |
| 06/06/2023 | Buy Now | 77.11% | HC Wainwright & Co. | Mitchell Kapoor | $77 → $82 | Maintains | Buy | Get Alert |
| 05/25/2023 | Buy Now | — | William Blair | Sami Corwin | — | Initiates | → Market Perform | Get Alert |
| 05/22/2023 | Buy Now | — | Daiwa Capital | Wilfred Yuen | — | Initiates | → Buy | Get Alert |
| 05/22/2023 | Buy Now | 66.31% | HC Wainwright & Co. | Mitchell Kapoor | → $77 | Reiterates | Buy → Buy | Get Alert |
| 05/19/2023 | Buy Now | 79.27% | RBC Capital | Leonid Timashev | $74 → $83 | Maintains | Outperform | Get Alert |
| 05/19/2023 | Buy Now | 94.38% | Barclays | Gena Wang | $65 → $90 | Maintains | Overweight | Get Alert |
| 04/25/2023 | Buy Now | 94.38% | BMO Capital | Kostas Biliouris | $79 → $90 | Maintains | Outperform | Get Alert |
| 04/20/2023 | Buy Now | 66.31% | HC Wainwright & Co. | Mitchell Kapoor | $66 → $77 | Maintains | Buy | Get Alert |
| 04/20/2023 | Buy Now | 83.59% | BTIG | Justin Zelin | $75 → $85 | Maintains | Buy | Get Alert |
| 04/19/2023 | Buy Now | 64.15% | JP Morgan | Jessica Fye | $65 → $76 | Maintains | Overweight | Get Alert |
| 04/18/2023 | Buy Now | 42.55% | HC Wainwright & Co. | Mitchell Kapoor | → $66 | Reiterates | → Buy | Get Alert |
| 04/12/2023 | Buy Now | 42.55% | HC Wainwright & Co. | Mitchell Kapoor | → $66 | Reiterates | → Buy | Get Alert |
| 04/03/2023 | Buy Now | 42.55% | HC Wainwright & Co. | Mitchell Kapoor | → $66 | Reiterates | → Buy | Get Alert |
| 03/29/2023 | Buy Now | 42.55% | HC Wainwright & Co. | Mitchell Kapoor | → $66 | Initiates | → Buy | Get Alert |
| 03/24/2023 | Buy Now | 57.67% | RBC Capital | Leonid Timashev | → $73 | Initiates | → Outperform | Get Alert |
| 01/25/2023 | Buy Now | 40.39% | Barclays | Gena Wang | $53 → $65 | Maintains | Overweight | Get Alert |
| 01/24/2023 | Buy Now | 40.39% | Morgan Stanley | Matthew Harrison | $60 → $65 | Maintains | Overweight | Get Alert |
| 12/20/2022 | Buy Now | 68.47% | Piper Sandler | Edward Tenthoff | $72 → $78 | Maintains | Overweight | Get Alert |
| 12/06/2022 | Buy Now | 40.39% | JP Morgan | Jessica Fye | $61 → $65 | Maintains | Overweight | Get Alert |
| 12/06/2022 | Buy Now | 42.55% | UBS | Ashwani Verma | → $66 | Initiates | → Buy | Get Alert |
| 11/02/2022 | Buy Now | — | Evercore ISI Group | Umer Raffat | — | Initiates | → Outperform | Get Alert |
| 11/01/2022 | Buy Now | — | Cowen & Co. | Yaron Werber | — | Initiates | → Outperform | Get Alert |
| 10/31/2022 | Buy Now | — | Guggenheim | Kelsey Goodwin | — | Initiates | → Neutral | Get Alert |
| 10/13/2022 | Buy Now | 29.59% | Morgan Stanley | Matthew Harrison | $63 → $60 | Maintains | Overweight | Get Alert |
| 07/15/2022 | Buy Now | 36.07% | Morgan Stanley | Matthew Harrison | $55 → $63 | Maintains | Overweight | Get Alert |
| 06/17/2022 | Buy Now | 66.31% | BMO Capital | Kostas Biliouris | → $77 | Initiates | → Outperform | Get Alert |
| 03/15/2022 | Buy Now | 14.47% | Barclays | Gena Wang | → $53 | Initiates | → Overweight | Get Alert |
| 03/07/2022 | Buy Now | 18.79% | Morgan Stanley | Matthew Harrison | $51 → $55 | Maintains | Overweight | Get Alert |
| 01/31/2022 | Buy Now | 10.15% | Morgan Stanley | Matthew Harrison | → $51 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 01/06/2022 | Buy Now | — | Morgan Stanley | Matthew Harrison | — | Downgrade | Overweight → Equal-Weight | Get Alert |
| 12/21/2021 | Buy Now | 42.55% | Piper Sandler | Edward Tenthoff | → $66 | Initiates | → Overweight | Get Alert |
| 10/12/2021 | Buy Now | 10.15% | Morgan Stanley | Matthew Harrison | — | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Legend Biotech (LEGN) stock?
The latest price target for Legend Biotech (NASDAQ:LEGN) was reported by BMO Capital on July 3, 2024. The analyst firm set a price target for $90.00 expecting LEGN to rise to within 12 months (a possible 94.38% upside). 34 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Legend Biotech (LEGN)?
The latest analyst rating for Legend Biotech (NASDAQ:LEGN) was provided by BMO Capital, and Legend Biotech maintained their outperform rating.
When was the last upgrade for Legend Biotech (LEGN)?
The last upgrade for Legend Biotech Corp happened on April 17, 2024 when Scotiabank raised their price target to $65. Scotiabank previously had a sector perform for Legend Biotech Corp.
When was the last downgrade for Legend Biotech (LEGN)?
The last downgrade for Legend Biotech Corp happened on January 6, 2022 when Morgan Stanley changed their price target from N/A to N/A for Legend Biotech Corp.
When is the next analyst rating going to be posted or updated for Legend Biotech (LEGN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Legend Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Legend Biotech was filed on July 3, 2024 so you should expect the next rating to be made available sometime around July 3, 2025.
Is the Analyst Rating Legend Biotech (LEGN) correct?
While ratings are subjective and will change, the latest Legend Biotech (LEGN) rating was a maintained with a price target of $90.00 to $90.00. The current price Legend Biotech (LEGN) is trading at is $46.30, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.